ConCallIQ
Go Pro
Home › Aarti Pharmalabs › Revenue History

Aarti Pharmalabs Revenue History — Quarter by Quarter

Aarti Pharmalabs's revenue moved from ₹386 Cr in Q1 FY26 to ₹583 Cr in Q4 FY26, a 51.0% change over 3 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q4 FY26₹583 Cr+9.4%
Q3 FY26₹432 Cr+15.1%
Q1 FY26₹386 Cr-30.5%

What management said about revenue

G

Q4 FY26 · Revenue and EBITDA growth of 15-18% over next 3-4 years

Management targets 15-18% CAGR in both revenue and EBITDA for the medium term, driven by capacity ramp-up and CDMO growth.

G

Q4 FY26 · CDMO segment to grow 40-50% in FY27

CDMO/CMO business expected to lead growth with projected sales growth of 40-50% in FY27.

G

Q3 FY26 · FY26 EBITDA flat to marginal growth

Management expects FY26 EBITDA to be largely in line with last year with only marginal growth, revised down from earlier expectations due to Atali delays and API softness.

G

Q3 FY26 · CDMO revenue guidance for FY26 maintained

Management is confident of meeting the CDMO revenue guidance for FY26, though exceeding the target is now difficult due to project delays.

G

Q1 FY26 · Standalone EBITDA growth of 12-15% for FY26

Management reiterated standalone EBITDA growth guidance of 12-15% for FY26, supported by margin expansion and CDMO ramp-up.

G

Q1 FY26 · CDMO revenue growth of 35-40% in FY26

CDMO segment expected to grow 35-40% YoY in FY26, driven by a strong order book and new capacities at Atali.